
What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

The approval of medications like statins and PCSK9 inhibitors to help lower cholesterol levels have proven helpful but a recent study looked at whether patients were getting not only the treatments they needed but whether they were getting the right dosage levels to help improve their health.

What happens when a patient with type 2 diabetes uses both a potassium (K)-sparing agent and sodium-glucose co-transporter 2 (SGLT2) inhibitor at the same time?

Resistant hypertension? A hypertensive emergency? Select your strategy and then find out if the evidence supports it.

There are many ways patients can better manage their cholesterol than they could just a few years ago. Whether they are successful in those efforts and the role of doctors and medications in that process remains to be seen.

Even as technology improves to help patients dealing with cardiovascular disease, those responsible for the procedures also must consider providing treatment while weighing the costs of that work.

The American College of Cardiology's outgoing President Kim A. Williams, MD, went vegan in 2003 and never looked back. He talks about the diet's power to heal and how being the ACC's first vegan leader played out.

For those how enter the field of genetic testing there are many challenges along the way, starting with finding the right training program through using that training in very difficult situations.

Find out what you know about how to avoid therapeutic inertia in treatment of hypertension.

Despite a considerable gap between the number of patients who require a transplant and the number of organs available those patients fortunate enough to receive the lifesaving organs are seeing greater success from the procedure.

There is no shortage of people in need of a kidney transplant but a considerable shortage in the number of organs available to these patients. Despite that health care professionals in nephrology are determined to provide their patients the highest quality of life possible in spite of these challenges.

As with all areas of health care money is an important consideration for hospitals and other medical research institutions. Finding the most effective way to spend money to get the best results can be a difficult balancing act across the board.

As technology improves and more is learned about treatment for various conditions new guidelines are constantly being developed in the medical field. Once the guidelines are updated it becomes even more important to get that information into the field to help the patients who can benefit from them.

In the changing landscape of hospital medicine one of the largest areas of focus has been on readmission rates, this is also true for patients who are discharged from one hospital and then readmitted into another location for further treatment.

From cardiologists to physical therapists to nurses there is a team approach needed to provide cardiac patients the care they need for treatment. Keeping that care going even after a cardiac event has passed has been a growing focus of the field in recent years.

Even in hospital settings patients can suffer fatal cardiac events if they are not properly monitored. This is especially true at night when staffing numbers drop and families are not with their loved ones until morning.

After much criticism on the price of 2 new cholesterol-lowering drugs, Praluent and Repatha, Express Scripts said this week it will now include both drugs in its National Preferred Formulary.

Heart disease is a growing problem in the country and work has been done to improve the overall public health through a number of steps including cardiac imaging. That work is also focused on the proper blood pressure for patients of all ages.

There could be a new first-line treatment for hypertension in patients needing diuretic therapy, according to research presented at the European Society of Cardiology (ESC) Congress conference in London, UK.

With a rallying cry of "Hands off Our Legs" protestors are due to picket the US Department of Health and Human Services over a proposed Medicare rule change that would affect amputees.

Anterior ischemic optic neuropathy (AION) was first described in 1974. It results from non-perfusion of the posterior ciliary blood supply to the optic nerve head.

A recent study looked at whether metabolic syndrome confers a greater cancer risk than the sum of its individual components and component associations, and whether it is a useful predictor for future cancer risk.

A drug normally used to treat hypertension reduced the symptoms of multiple sclerosis in mice models of the disease.

Obesity rates have climbed nearly 50 percent since 1997, with as much as 30 percent of the population classified as obese. There is strong belief within the health care industry that obesity should be treated as a primary medical condition, with physicians playing a major role. Evidence suggests that patients are more likely to lose weight when they are advised by their primary care physicians to do so.

The results of the largest study of its kind to date indicate that new antipsychotic medications-including quetiapine, olanzapine, and risperidone-do not appear to put women at additional risk of developing gestational diabetes, hypertensive disorders, or major blood clots that obstruct circulation, all conditions that often develop during pregnancy or with the use of older antipsychotic medications.

Hypertension needs to be managed quickly and carefully for patients to avoid health problems

More than 13,000 physicians and cardiovascular team members attended the ACC 2015 meeting in San Diego on March 14-16, 2015. In this issue of Cardiology Review, we focus on 6 important studies presented at ACC 2015: LEGACY, OSLER, PEGASUS, EMBRACE-STEMI, MATRIX, and CoreValve.